An observational study in Nephroblastoma, sponsored by French Africa Pediatric Oncology Group. Recruiting at 7 sites in 6 countries. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by French Africa Pediatric Oncology Group · Observational
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.
200 studies on the registry are indexed under Wilms Tumor; 25 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 162 across 36 observational studies indexed under Wilms Tumor.
Browse Wilms Tumor studies →French Africa Pediatric Oncology Group is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All children with local Nephroblastoma in all participating units
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.
.
Exclusion Criteria:
Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal
All children coming into the participating units with suspected Nephroblastoma.
Other: Data collection
Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
Evaluation of the number of cases with local disease.
By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.
Time frame: 5 years
Evaluation of the number of cases with stage IV disease.
By evaluating the initial clinical reports and later histological reports to confirm the stage.
Time frame: 5 Years
Evaluating the treatment given.
Comparison of treatment given and recommended treatment.
Time frame: 5 Years
Evaluating the follow up after treatment.
How many children alive or dead after treatment
Time frame: 5 Years
Why has treatment failed
look at precision of reporting by comparing reports (histological and surgical)
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Africa Pediatric Oncology Group